Table I. (A) Clinical profile of patients with malignant gliomas and (B) their CSF profiles. GBM, glioblastoma; AOA, anaplastic oligoastrocytoma; and AA, anaplastic astrocytoma; XRT, radiation therapy; TMZ, temozolomide; and CPT-11, irinotecan. Newly Diagnosed (N), Recurrent (R). Δ(Initial–Sample Date) (time from diagnosis to sample collection). WBC–White Blood Cell Count (number/μl), Protein (mg/dL), Glucose (mg/dL), LDH (International Units/L). T1 GAD–2D tumor size estimate from Gadolinium MRI. FLAIR–2D tumor size estimate from FLAIR MRI.

A
Patient	Age	Gender	DIAGNOSIS	Newly Diagnosed or Recurrent	Δ (Initial - Sample Date) (months)	Survival (months)
1	61	M	GBM	N	0	8
2	59	M	GBM	N	0	9
3	45	F	AOA	R	34	34
4	67	M	GBM	R	9	17
5	57	M	AOA	N	0	21
6	27	F	AA	R	3	27
7	55	M	GBM	N	0	37
8	41	F	AA	R	8	27
9	52	M	GBM	R	7	18
10	46	F	GBM	R	12	14

B
Patient	WBC	Protein	Glucose	LDH	T1 Gad (cm2)	FLAIR (cm2)	Δ (FLAIR - T1 Gad) (cm2)	Treatment
1	2	23	63	11	1	23.8	22.8
2	2	47	70	9	5.7	37.6	31.9
3	3	209	87	N/A	9	39.1	30.1	XRT, TMZ, Avastin, CPT-11
4	1	96	67	56	23.9	43.6	19.7	XRT, TMZ, ZD6474, NovoTTF
5	2	63	63	19	0.7	11.6	10.9
6	3	61	93	N/A	2.6	3.7	1.1	XRT, TMZ
7	1	51	73	26	1.2	36.5	35.3
8	5	57	77	22	0.6	13.2	12.6	XRT, TMZ, Avastin, CPT-11
9	1	41	63	N/A	17.6	28.5	10.9	XRT, TMZ, NovoTTF
10	4	158	76	56	10.2	37.6	27.4	XRT, TMZ, CPT-11